Abstract 2159P
Background
The International Society for Geriatric Oncology (SIOG) recommends the use of geriatric assessments (GA) or clinical adverse event risk predictors when managing older cancer patients. However, traditional GA and risk predictors are rarely utilized in the real-world setting due to limitations in time and resources. The objective of this study was to assess the performance of machine learning algorithms in predicting the risk of post-chemotherapy grade 3-5 toxicity in older Asian patients.
Methods
This study is based on a dataset of patients from a prospective study at the National University Cancer Institute, Singapore (NCIS) that successfully validated the CARG model in older Asian patients. In this study, 200 patients aged 70 years or older of various Asian ethnicities, with a solid tumor diagnosis and undergoing chemotherapy were prospectively recruited over the period of June 1, 2017, to January 1, 2019. We trained four machine learning models – Support Vector Machine (SVM), Random Forest (RF), Extreme Gradient Boosting (Xgboost), and Light Gradient Boosting Machine (Light DBM) to predict the outcomes of grade 3-5 (CTCAE version 4.0) adverse events post-chemotherapy.
Results
The median patient age was 74 years (IQR, 71 to 78), and 110 (55.0%) were male. 137 (68.5%) patients experienced grade 3 to 5 chemotherapy toxicity. The best-performing model for predicting grade 3-5 chemotherapy toxicity in the test set was the Xgboost model which achieved an area under the ROC curve (AUC) of 0.87. By comparison, the CARG clinical model and oncologist prediction of grade 3-5 toxicity achieved an AUC of 0.61 and 0.74 respectively in the test set. The best performing Xgboost model included elements of the CARG model in addition to clinical features such as the Karnofsky Performance Scale, number of co-morbidities and medications, current treatment line, “Timed-Up and Go”.
Conclusions
The Xgboost Machine Learning model was able to predict the occurrence of grade 3-5 toxicity post-chemotherapy in elderly Asian patients with a better performance compared to the CARG clinical model and oncologists’ predictions. These results will be further evaluated in external, prospective patient cohorts to validate them for clinical use.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National University Cancer Institute, Singapore.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2194P - Prospective observational study of physical activity measurement using wearable device as an alternative to ECOG PS in patients with advanced lung cancer
Presenter: Kentaro Ito
Session: Poster session 07
Resources:
Abstract
2195P - Targeted gene editing with CRISPR for the treatment of pleural mesothelioma
Presenter: Rodrigo Dominic Cerqueda
Session: Poster session 07
2196P - PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT
Presenter: Daniel C. Christoph
Session: Poster session 07
2197P - Prognostic value of 18F-FDG-PET for patients with malignant pleural mesothelioma treated with double immunotherapy
Presenter: Solfrid Thunold
Session: Poster session 07
2198P - Clinicopathologic characteristics and outcomes to immune checkpoint inhibitor therapy in patients with HER2-altered metastatic non-small cell lung cancer
Presenter: Maisam Makarem
Session: Poster session 07
2199P - Immunohistochemical identification of clinical subtypes and potential therapeutic vulnerabilities of lung carcinoids based on multi-omic analysis
Presenter: Jules Derks
Session: Poster session 07
2200P - Spatiotemporal distribution of mediastinal neoplasms: A multi-center, hospital-based, systematic analysis
Presenter: Yu Jiang
Session: Poster session 07
2201P - Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies
Presenter: Sabine Schmid
Session: Poster session 07
2202P - Large cell neuroendocrine carcinoma (LCNEC) subtyping based on NEUROD1, ASCL1, POU2F3 and YAP1 expression
Presenter: Frank Heijboer
Session: Poster session 07
2203P - Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma
Presenter: Mario Occhipinti
Session: Poster session 07